Michael Ulz
Stock Analyst at Morgan Stanley
(4.55)
# 269
Out of 5,006 analysts
94
Total ratings
57.14%
Success rate
28.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $71 → $86 | $69.42 | +23.88% | 6 | Sep 23, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $42 → $25 | $6.49 | +285.21% | 7 | Aug 12, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $312 → $405 | $455.06 | -11.00% | 11 | Aug 1, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $5.06 | +394.56% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $32.00 | +218.75% | 3 | Apr 24, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $5.71 | +250.26% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.40 | +816.67% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $16.17 | +79.34% | 1 | Mar 10, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $2.31 | +767.68% | 4 | Feb 28, 2025 | |
| GUTS Fractyl Health | Maintains: Overweight | $18 → $10 | $1.54 | +549.35% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $45.76 | +109.79% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $13.05 | +298.47% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $72.72 | -21.62% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $37.90 | -28.76% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.31 | +434.35% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $12.45 | +116.87% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.59 | +1,157.86% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.20 | +1,306.25% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.84 | +1,090.48% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.73 | -36.58% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.72 | +424.48% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $8.30 | +5,924.10% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $31.53 | +153.73% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $8.16 | +83.82% | 3 | Jul 12, 2017 |
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Overweight
Price Target: $71 → $86
Current: $69.42
Upside: +23.88%
Karyopharm Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $25
Current: $6.49
Upside: +285.21%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $312 → $405
Current: $455.06
Upside: -11.00%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.06
Upside: +394.56%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $32.00
Upside: +218.75%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $5.71
Upside: +250.26%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.40
Upside: +816.67%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $16.17
Upside: +79.34%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.31
Upside: +767.68%
Fractyl Health
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.54
Upside: +549.35%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $45.76
Upside: +109.79%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $13.05
Upside: +298.47%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $72.72
Upside: -21.62%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $37.90
Upside: -28.76%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.31
Upside: +434.35%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $12.45
Upside: +116.87%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.59
Upside: +1,157.86%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.20
Upside: +1,306.25%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.84
Upside: +1,090.48%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.73
Upside: -36.58%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.72
Upside: +424.48%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $8.30
Upside: +5,924.10%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $31.53
Upside: +153.73%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $8.16
Upside: +83.82%